每经AI快讯，民生健康1月7日晚间发布公告称，截至2025年12月31日，杭州民生健康药业股份有限公 司通过回购专用证券账户，以集中竞价交易方式已累计回购股份约100万股，占目前公司总股本的比例 为0.28%，最高成交价为15.67元/股，最低成交价为14.39元/股，支付金额约为1500万元。 （记者 曾健辉） 每经头条（nbdtoutiao）——十年首现，沪指连续站稳关键位置！高盛：建议高配中国股票！券商分析 师：人民币升值等因素加速跨境资本回流 ...

证券代码：301507 证券简称：民生健康 公告编号：2026-001 杭州民生健康药业股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 第二期回购方案的实施情况：截至 2025 年 12 月 31 日，杭州民生健康药 业股份有限公司（以下简称"公司"）通过回购专用证券账户，以集中竞价交易方 式已累计回购股份 996,900 股，占目前公司总股本的比例为 0.28%，最高成交价 为 15.67 元/股，最低成交价为 14.39 元/股，支付金额为 14,999,327.00 元（不含 交易费用）。 一、回购股份的基本情况 公司于 2025 年 10 月 28 日召开第二届董事会第十一次会议，审议通过《关 于第二期以集中竞价交易方式回购公司股份的议案》，同意公司以自有资金通过 集中竞价交易方式实施第二期公司股份回购，用于股权激励。回购价格不超过公 司董事会审议通过回购股份决议前三十个交易日公司股票交易均价的 150%，即 人民币 21.06 元/股；预计回购股份数量为 210 ...

Core Insights - The Chinese health consumption market is undergoing a significant transformation, shifting from "wild growth" to "meticulous cultivation," with competition evolving into an ecosystem-based contest [1][2] - The health management market in China is projected to exceed 850 billion yuan in 2024, with a compound annual growth rate of 21.3%, expected to surpass 2.3 trillion yuan by 2030 [2] - The rise of rational consumption, particularly among younger consumers, emphasizes the importance of product transparency and scientific communication [3] Industry Trends - The traditional model of health services is being replaced by a comprehensive health management approach, focusing on the entire lifecycle of health rather than one-time services [4] - Companies are increasingly adopting integrated health solutions that combine products and services, moving away from merely selling individual items [3][4] Company Strategies - Minsheng Health is pursuing a diversified expansion strategy, targeting various segments within the health sector, including nutritional supplements and medical aesthetics [6] - In contrast, Meinian Health is focusing on deep specialization in preventive medicine, establishing a clear brand hierarchy to serve different market segments [6] - Both companies are building health management ecosystems, with Meinian leveraging its extensive health data for AI development and personalized health management [7] - Minsheng Health emphasizes collaboration across the supply chain, particularly in the probiotics sector, to enhance product quality and technological competitiveness [8]

Core Viewpoint - The 2025 "Responsibility Shining in Qilu" annual ceremony recognized Shandong New Zhonglu Traditional Chinese Medicine Hospital for its outstanding contributions in the fields of traditional Chinese medicine innovation, quality medical service provision, and public health communication [1][3]. Group 1: Event Overview - The event was organized by the Shandong Provincial Health Commission and Shandong Digital Culture Group, with participation from leaders and representatives of nearly a hundred medical institutions in Shandong [3]. - The evaluation for the annual responsibility awards involved public recommendations, sentiment analysis, big data assessment, and reader feedback, aiming to honor institutions and individuals that made significant contributions to the development of health services in Shandong [3]. Group 2: Hospital Achievements - Since its establishment, Shandong New Zhonglu Traditional Chinese Medicine Hospital has adhered to its motto of "thick virtue and compassion, diligent in serving the world," focusing on the mission of inheriting and promoting traditional Chinese medicine [3]. - The hospital has gathered high-end talents, including national medical masters and renowned traditional Chinese medicine practitioners, to enhance its medical services, particularly in key departments like internal medicine [3]. - The hospital emphasizes a "preventive treatment" philosophy, providing personalized adjustment services for chronic disease patients and those in sub-health conditions, which has earned public trust [3]. Group 3: Public Health Initiatives - The hospital has actively engaged in public health communication, organizing over 200 large-scale free medical consultation events in 2023, and has established a team of skilled traditional Chinese medicine experts to provide free medical services [4]. - In 2025, the hospital will continue its "Health into Thousands of Homes" initiative, offering health screenings and personalized adjustment plans to employees in various enterprises [4]. - The hospital achieved significant milestones in 2025, including the opening of a new facility, the commencement of the third Medicinal Paste Festival, and the establishment of a Traditional Chinese Medicine Lifestyle Promotion Base [4]. Group 4: Future Directions - The hospital's director stated that receiving the annual responsibility award is a recognition of the hospital's work and a commitment to continue enhancing the core values of traditional Chinese medicine [5]. - The hospital aims to deepen the innovation of traditional Chinese medicine and expand its public health services, responding to the 2026 "One Point Asking for Medical Advice" initiative for national health protection [5]. - The hospital plans to provide more convenient and quality traditional Chinese medicine health services through a combination of online education and offline services, contributing to the high-quality development of traditional Chinese medicine [5].

Core Viewpoint - The event held on December 27, 2025, recognized various honors in the healthcare sector, with Shandong University of Traditional Chinese Medicine Affiliated Hospital being awarded the "Responsible Hospital" title for its commitment to public health and medical responsibility [1][3]. Group 1: Hospital Achievements - 2025 marks a significant year for the Shandong University of Traditional Chinese Medicine Affiliated Hospital as it celebrates its 70th anniversary, emphasizing its role as a leading institution in traditional Chinese medicine [3]. - The hospital has established a top-tier diagnostic team led by renowned traditional Chinese medicine experts, focusing on difficult and major diseases, and has developed several key specialty clusters [3][4]. - The hospital has implemented a comprehensive health management system that emphasizes preventive care and personalized services, enhancing patient satisfaction and access to healthcare [3][4]. Group 2: Educational and Community Engagement - The hospital is committed to the integration of teaching, medical care, and research, facilitating the transmission of traditional Chinese medicine knowledge through mentorship and collaboration with educational institutions [4]. - In 2025, the hospital launched a health promotion initiative that includes free medical consultations and health screenings in rural and community settings, addressing the needs of underserved populations [4][5]. - The hospital utilizes new media platforms to disseminate health knowledge and engage with the community, including educational activities in schools to promote traditional Chinese medicine culture among youth [5]. Group 3: Future Outlook - The event served as a reflection on the achievements of the healthcare sector in Shandong in 2025 and a strategic planning session for future developments [5]. - The hospital aims to leverage its 70th anniversary as a new starting point to continue its mission of safeguarding public health through traditional Chinese medicine [5].

Group 1 - The second Jiangsu Province Maternal and Child Health High-Quality Development Conference was held on December 27, focusing on "Innovative Cooperation Leading" [2] - A strategic cooperation agreement was signed between Jiangsu Province Maternal and Child Health Hospital and Fudan University Affiliated Obstetrics and Gynecology Hospital, marking the entry of top-tier medical resources into Jiangsu [2][4] - The collaboration aims to enhance local healthcare services, allowing residents to access national-level medical services without traveling far [2] Group 2 - The partnership will leverage expert resources, research platforms, and talent training systems to improve diagnosis and treatment in key areas such as gynecological tumors and reproductive health [4] - The hospital plans to establish specialized diagnostic centers, share research innovations, and cultivate professional talent to elevate local healthcare capabilities [4][6] - The strategic collaboration is seen as a foundation for improving maternal and child health services, contributing to the overall health of families and society [6] Group 3 - A large-scale free clinic event featuring experts from Shanghai's Red House Hospital was held concurrently, allowing citizens to benefit from the health services provided by the new partnership [8]

Core Viewpoint - Sichuan Province is actively promoting the HPV vaccine through various initiatives aimed at improving public health, including expanding the target population, reducing vaccine costs, and optimizing service processes [1][2][3] Group 1: HPV Vaccine Promotion - The HPV vaccination program will begin in 2025 across several cities and counties in Sichuan, with specific measures such as extending the vaccination period and providing cost reductions for certain age groups [1] - Eligible individuals aged 9-26 years and 35-45 years for females, as well as 16-26 years for males, can receive a cost reduction for the final dose of the imported nine-valent HPV vaccine [1][2] - The vaccination schedule for girls aged 9-14 allows for a two-dose regimen where the first dose is charged and the second dose is free [1] Group 2: Health Impact and Statistics - The incidence of cervical cancer in China has been rising, with nearly 150,000 new cases and 60,000 deaths reported in 2022, highlighting the importance of preventive measures [2] - The World Health Organization emphasizes that cervical cancer is preventable, and the 2023 guidelines recommend health education and HPV vaccination as primary prevention strategies [2] Group 3: Guidelines and Recommendations - The "Clinical Application Guidelines for Preventive HPV Vaccines in China (2025 Edition)" recommend prioritizing HPV vaccination for females aged 9-26, particularly focusing on girls aged 9-14 [3] - The initiatives in Sichuan reflect a commitment to implementing scientific recommendations and aim to establish a herd immunity barrier by including males and other age groups in the vaccination program [3] - The policies are designed to enhance public willingness to vaccinate by lowering costs and improving service accessibility, with extended service periods and appointment windows [3]

Group 1: Overseas News - US stock market has seen five consecutive days of gains, with the Dow Jones up 0.6%, Nasdaq up 0.22%, and S&P 500 up 0.32%. Major tech companies like Apple, Meta, Microsoft, and Amazon saw increases of up to 0.53%, while Tesla, Google A, and Nvidia experienced declines of up to 0.32% [1] - Nvidia denied reports of a $200 million acquisition of AI chip startup Groq, stating that only a licensing agreement for inference technology was reached [1] - Samsung and SK Hynix are reportedly raising HBM3E prices by nearly 20% for next year [1] - Sanofi plans to acquire US vaccine company Dynavax for $2.2 billion to enhance its adult vaccine portfolio [1] Group 2: Domestic Major Events - The People's Bank of China and eight other departments issued opinions to support the construction of the Western Land-Sea New Corridor, exploring cross-border payment trials for digital RMB with Singapore [2][5] Group 3: Market Strategy Insights - Everbright Securities noted that the Shanghai Composite Index has shown strong performance with six consecutive days of gains, indicating a recovery in market sentiment and potential continued inflow of funds, particularly favoring technology growth stocks [3] Group 4: Real Estate Policy Changes - Beijing's new real estate policy, effective December 24, 2025, includes four main aspects: relaxing social security requirements for non-Beijing residents, supporting multi-child families in housing needs, optimizing commercial loan interest rates, and lowering the down payment ratio for second homes [4][5] Group 5: Digital Currency Developments - The digital RMB aims to address inefficiencies and high costs in traditional cross-border payments, with optimistic projections for transaction volumes reaching 162.4 trillion yuan by 2030 [6]

Group 1 - The "Beijing Brain No. 1" brain-computer interface system has enabled high-level paraplegic patients to perform actions like grasping a cup using only their thoughts, showcasing innovation in the medical field [1] - The Beijing medical and health industry is projected to reach a total scale of 1.06 trillion yuan by 2024, driven by innovation in medical devices and AI, with the highest number of approved innovative medical devices in the country [1] - The Beijing Economic and Technological Development Zone hosts over 5,000 biopharmaceutical companies, covering all areas of the medical and health industry, including biopharmaceuticals, modern traditional Chinese medicine, new vaccines, and high-end medical equipment [1] Group 2 - AstraZeneca has officially launched its global R&D strategic center in Beijing, which will leverage the local scientific ecosystem and AI advantages to accelerate the development of next-generation innovative drugs [2] - The Beijing government has implemented a series of "32 measures" to address industry development bottlenecks, significantly reducing the median time for clinical trial initiation to 21.4 weeks and expediting the approval process for innovative drug projects [2] - Beijing is promoting dual-directional efforts in basic research and results transformation through targeted policies in synthetic biology, cell, and gene therapy, with a new gene drug for treating blindness set to begin trials in January 2024 [3] Group 3 - A new 20 billion yuan special industrial fund has been established to support the pharmaceutical and health sector, with 77 projects already approved for funding [3] - The "South-North linkage" strategy in Beijing aims to create a synergistic spatial layout, with the southern economic development zone focusing on global pharmaceutical talent and the northern area concentrating on original innovation and future industries [3] - The Beijing government plans to accelerate the integration of technological innovation and industrial innovation in the pharmaceutical industry, enhancing the smart and green levels of the entire pharmaceutical industrial chain [4]

证券代码：301507 证券简称：民生健康 公告编号：2025-057 特别提示： 1、本次解除限售的股份为杭州民生健康药业股份有限公司（以下简称"公 司"）2024年限制性股票激励计划（以下简称"《激励计划》"或"本激励计划"） 首次授予部分第一个归属期已归属的限制性股票 2、本次解除限售股东户数共计40户，解除限售股份的数量为1,328,000股， 占目前公司总股本的0.37% 3、本次解除限售的股份上市流通日期为2025年12月26日（星期五） 杭州民生健康药业股份有限公司 关于 2024 年限制性股票激励计划首次授予部分 第一个归属期已归属股票上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 （三）限制性股票授予价格：本激励计划首次授予激励对象限制性股票的授 予价格为 6.67 元/股（权益分派调整前），预留部分限制性股票授予价格与首次 授予的限制性股票授予价格相同。 一、激励计划首次授予部分第一个归属期归属的限制性股票的限售安排 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《激 励计划》、《深圳证券交易所创 ...